356 related articles for article (PubMed ID: 23414607)
21. The effect of aging on OX40 agonist-mediated cancer immunotherapy.
Ruby CE; Weinberg AD
Cancer Immunol Immunother; 2009 Dec; 58(12):1941-7. PubMed ID: 19288101
[TBL] [Abstract][Full Text] [Related]
22. PLGA-nanoparticle mediated delivery of anti-OX40 monoclonal antibody enhances anti-tumor cytotoxic T cell responses.
Chen M; Ouyang H; Zhou S; Li J; Ye Y
Cell Immunol; 2014 Feb; 287(2):91-9. PubMed ID: 24487032
[TBL] [Abstract][Full Text] [Related]
23. DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity.
Muik A; Adams 3rd HC; Gieseke F; Altintas I; Schoedel KB; Blum JM; Sänger B; Burm SM; Stanganello E; Verzijl D; Spires VM; Vascotto F; Toker A; Quinkhardt J; Fereshteh M; Diken M; Satijn DPE; Kreiter S; Ahmadi T; Breij ECW; Türeci Ö; Sasser K; Sahin U; Jure-Kunkel M
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688554
[TBL] [Abstract][Full Text] [Related]
24. Using Antigen-Specific B Cells to Combine Antibody and T Cell-Based Cancer Immunotherapy.
Wennhold K; Thelen M; Schlößer HA; Haustein N; Reuter S; Garcia-Marquez M; Lechner A; Kobold S; Rataj F; Utermöhlen O; Chakupurakal G; Theurich S; Hallek M; Abken H; Shimabukuro-Vornhagen A; von Bergwelt-Baildon M
Cancer Immunol Res; 2017 Sep; 5(9):730-743. PubMed ID: 28778961
[TBL] [Abstract][Full Text] [Related]
25. CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement.
Gaspar M; Pravin J; Rodrigues L; Uhlenbroich S; Everett KL; Wollerton F; Morrow M; Tuna M; Brewis N
Cancer Immunol Res; 2020 Jun; 8(6):781-793. PubMed ID: 32273279
[TBL] [Abstract][Full Text] [Related]
26. Costimulation of T cells by OX40, 4-1BB, and CD27.
Croft M
Cytokine Growth Factor Rev; 2003; 14(3-4):265-73. PubMed ID: 12787564
[TBL] [Abstract][Full Text] [Related]
27. Rationale for anti-OX40 cancer immunotherapy.
Aspeslagh S; Postel-Vinay S; Rusakiewicz S; Soria JC; Zitvogel L; Marabelle A
Eur J Cancer; 2016 Jan; 52():50-66. PubMed ID: 26645943
[TBL] [Abstract][Full Text] [Related]
28. The significance of OX40 and OX40L to T-cell biology and immune disease.
Croft M; So T; Duan W; Soroosh P
Immunol Rev; 2009 May; 229(1):173-91. PubMed ID: 19426222
[TBL] [Abstract][Full Text] [Related]
29. Functional dichotomy between OX40 and 4-1BB in modulating effector CD8 T cell responses.
Lee SW; Park Y; Song A; Cheroutre H; Kwon BS; Croft M
J Immunol; 2006 Oct; 177(7):4464-72. PubMed ID: 16982882
[TBL] [Abstract][Full Text] [Related]
30. A mathematical model of combined CD8 T cell costimulation by 4-1BB (CD137) and OX40 (CD134) receptors.
Konstorum A; Vella AT; Adler AJ; Laubenbacher RC
Sci Rep; 2019 Jul; 9(1):10862. PubMed ID: 31350431
[TBL] [Abstract][Full Text] [Related]
31. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection.
Piconese S; Valzasina B; Colombo MP
J Exp Med; 2008 Apr; 205(4):825-39. PubMed ID: 18362171
[TBL] [Abstract][Full Text] [Related]
32. Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells.
Hippen KL; Harker-Murray P; Porter SB; Merkel SC; Londer A; Taylor DK; Bina M; Panoskaltsis-Mortari A; Rubinstein P; Van Rooijen N; Golovina TN; Suhoski MM; Miller JS; Wagner JE; June CH; Riley JL; Blazar BR
Blood; 2008 Oct; 112(7):2847-57. PubMed ID: 18645038
[TBL] [Abstract][Full Text] [Related]
33. The weal and woe of costimulation in the adoptive therapy of cancer with chimeric antigen receptor (CAR)-redirected T cells.
Hombach AA; Holzinger A; Abken H
Curr Mol Med; 2013 Aug; 13(7):1079-88. PubMed ID: 23116267
[TBL] [Abstract][Full Text] [Related]
34. Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.
Ager CR; Reilley MJ; Nicholas C; Bartkowiak T; Jaiswal AR; Curran MA
Cancer Immunol Res; 2017 Aug; 5(8):676-684. PubMed ID: 28674082
[TBL] [Abstract][Full Text] [Related]
35. Immune regulation and control of regulatory T cells by OX40 and 4-1BB.
So T; Lee SW; Croft M
Cytokine Growth Factor Rev; 2008; 19(3-4):253-62. PubMed ID: 18508403
[TBL] [Abstract][Full Text] [Related]
36. 4-1BB agonism: adding the accelerator to cancer immunotherapy.
Chester C; Ambulkar S; Kohrt HE
Cancer Immunol Immunother; 2016 Oct; 65(10):1243-8. PubMed ID: 27034234
[TBL] [Abstract][Full Text] [Related]
37. OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment.
Bell RB; Leidner RS; Crittenden MR; Curti BD; Feng Z; Montler R; Gough MJ; Fox BA; Weinberg AD; Urba WJ
Oral Oncol; 2016 Jan; 52():1-10. PubMed ID: 26614363
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy of cancer with 4-1BB.
Vinay DS; Kwon BS
Mol Cancer Ther; 2012 May; 11(5):1062-70. PubMed ID: 22532596
[TBL] [Abstract][Full Text] [Related]
39. Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy.
Devaud C; Westwood JA; John LB; Flynn JK; Paquet-Fifield S; Duong CP; Yong CS; Pegram HJ; Stacker SA; Achen MG; Stewart TJ; Snyder LA; Teng MW; Smyth MJ; Darcy PK; Kershaw MH
Mol Ther; 2014 Jan; 22(1):18-27. PubMed ID: 24048441
[TBL] [Abstract][Full Text] [Related]
40. Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS.
Sanmamed MF; Pastor F; Rodriguez A; Perez-Gracia JL; Rodriguez-Ruiz ME; Jure-Kunkel M; Melero I
Semin Oncol; 2015 Aug; 42(4):640-55. PubMed ID: 26320067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]